In a recent research investigation, T. Amer and colleagues sought to epigenetically control two immune-modulating proteins, CD80 and mesothelin (MSLN), which are highly expressed in breast cancer and have pro-tumorigenic impacts [208], in order to modulate the anti-inflammatory properties of TAMs in various breast cancer subtypes (hormonal, HER2+, and TNBC). The gene discussed is CD80; the disease is breast cancer.